Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned an average rating of “Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $95.72.

Several research analysts recently weighed in on the company. Barclays PLC set a $90.00 target price on Charles River Laboratories International and gave the company a “hold” rating in a research note on Saturday, May 13th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price for the company in a research note on Wednesday. Jefferies Group LLC reaffirmed a “buy” rating and set a $121.00 target price on shares of Charles River Laboratories International in a research note on Friday, June 30th. Credit Suisse Group reaffirmed a “neutral” rating and set a $95.00 target price (up previously from $89.00) on shares of Charles River Laboratories International in a research note on Tuesday, June 6th. Finally, BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/16/charles-river-laboratories-international-inc-nysecrl-receives-95-21-average-pt-from-analysts-updated.html.

In other Charles River Laboratories International news, Director George Massaro sold 1,130 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $88.30, for a total value of $99,779.00. Following the transaction, the director now directly owns 15,831 shares of the company’s stock, valued at approximately $1,397,877.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David Ross Smith sold 945 shares of the stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $95.00, for a total value of $89,775.00. Following the transaction, the insider now directly owns 14,203 shares in the company, valued at approximately $1,349,285. The disclosure for this sale can be found here. Over the last three months, insiders sold 76,669 shares of company stock valued at $7,560,089. Company insiders own 2.20% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. raised its position in shares of Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock worth $135,000 after buying an additional 526 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Charles River Laboratories International by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock worth $147,000 after buying an additional 43 shares in the last quarter. Wsfs Capital Management LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $205,000. MAI Capital Management bought a new position in shares of Charles River Laboratories International during the first quarter worth approximately $224,000. Finally, Massmutual Trust Co. FSB ADV raised its position in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock worth $246,000 after buying an additional 130 shares in the last quarter. 97.61% of the stock is currently owned by institutional investors and hedge funds.

Shares of Charles River Laboratories International (NYSE CRL) traded down 0.09% on Monday, hitting $100.56. 160,733 shares of the stock were exchanged. The stock has a market cap of $4.79 billion, a PE ratio of 29.43 and a beta of 1.03. The company’s 50 day moving average is $94.16 and its 200-day moving average is $87.11. Charles River Laboratories International has a 52-week low of $67.20 and a 52-week high of $102.32.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The business had revenue of $445.80 million during the quarter, compared to analysts’ expectations of $437.04 million. During the same quarter last year, the business posted $0.98 earnings per share. The company’s quarterly revenue was up 25.6% on a year-over-year basis. Analysts predict that Charles River Laboratories International will post $5.10 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.